Stock Quote
Genzyme Corporation (GENZ.O) (Nasdaq)
$50.24
4:00pm EST
+0.38%
$50.05
$50.25
3,319,536
$50.90
$50.00
$73.75
$47.09
0.30
6,036,072
GENZ.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Termeer, Henri | Chairman of the Board, President, Chief Executive Officer | 13,773,800 |
| Wyzga, Michael | Chief Financial Officer, Executive Vice President - Finance | 3,019,200 |
| Wirth, Peter | Executive Vice President - Legal and Corporate Development, Secretary | 3,246,360 |
Profile
Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients... Full Description
Company Address
Genzyme Corporation
500 Kendall Street
Cambridge MA 02142
P: +1617.2527500
F: +1617.2527600
500 Kendall Street
Cambridge MA 02142
P: +1617.2527500
F: +1617.2527600
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Teva Pharmaceutical Industries Limited | ₪20,160.00 | 0.00 |
| Actelion Ltd | CHF59.45 | +0.75 |
| Shire Plc. | £1,159.00 | +24.00 |
| GENZ.O | Industry | |
|---|---|---|
| P/E(TTM) | 28.54 | 12.80 |
| P/S(TTM) | 2.94 | 29.90 |
| ROI(TTM) | 5.78 | 2.35 |
| ROE(TTM) | 6.54 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.76 |
| EPS Est. (Current Year) | 2.27 |
| Total Revenue | $1,057.51M |
| Net Income | $15.99M |
| EPS | $0.06 |
